Physician profile
Ehab Ali
NPI 1346680907
$872.30
in general payments reported to CMS, 2019-2025
22 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.19 · 2020: $77.52 · 2021: $200 · 2022: $89.87 · 2023: $175 · 2024: $101 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $143.96 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $91.73 | 2019-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $76.23 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $64.46 | 2020-2024 | |
| Corcept Therapeutics | $52.98 | 2021 | |
| Pfizer INC. | $49.48 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.95 | 2019-2022 | |
| Abbott Laboratories | $39.05 | 2021-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $32.52 | 2019 | |
| Daiichi Sankyo INC. | $30.71 | 2020-2021 | |
| Abbvie INC. | $29.80 | 2021 | |
| Lilly USA, LLC | $27.56 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $25.36 | 2021-2023 | Farxiga |
| Dexcom, INC. | $23.75 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $23.55 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.44 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.00 | 2022 | |
| Tandem Diabetes Care, INC. | $17.72 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $16.78 | 2023 | Myrbetriq |
| Horizon Therapeutics Plc | $15.24 | 2022 | |
| Glaxosmithkline, LLC. | $14.03 | 2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $14.00 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehab Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.